413 related articles for article (PubMed ID: 21527343)
1. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
[TBL] [Abstract][Full Text] [Related]
2. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
[TBL] [Abstract][Full Text] [Related]
3. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome.
Salehi A; Faizi M; Colas D; Valletta J; Laguna J; Takimoto-Kimura R; Kleschevnikov A; Wagner SL; Aisen P; Shamloo M; Mobley WC
Sci Transl Med; 2009 Nov; 1(7):7ra17. PubMed ID: 20368182
[TBL] [Abstract][Full Text] [Related]
4. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
[TBL] [Abstract][Full Text] [Related]
5. Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome.
Dang V; Medina B; Das D; Moghadam S; Martin KJ; Lin B; Naik P; Patel D; Nosheny R; Wesson Ashford J; Salehi A
Biol Psychiatry; 2014 Feb; 75(3):179-88. PubMed ID: 23827853
[TBL] [Abstract][Full Text] [Related]
6. β1-adrenergic receptor activation enhances memory in Alzheimer's disease model.
Coutellier L; Ardestani PM; Shamloo M
Ann Clin Transl Neurol; 2014 May; 1(5):348-360. PubMed ID: 24883337
[TBL] [Abstract][Full Text] [Related]
7. A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.
Lockrow J; Boger H; Gerhardt G; Aston-Jones G; Bachman D; Granholm AC
J Alzheimers Dis; 2011; 23(3):471-89. PubMed ID: 21098982
[TBL] [Abstract][Full Text] [Related]
8. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors.
Heller HC; Salehi A; Chuluun B; Das D; Lin B; Moghadam S; Garner CC; Colas D
Neurobiol Learn Mem; 2014 Dec; 116():162-71. PubMed ID: 25463650
[TBL] [Abstract][Full Text] [Related]
9. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test.
Costa AC; Scott-McKean JJ; Stasko MR
Neuropsychopharmacology; 2008 Jun; 33(7):1624-32. PubMed ID: 17700645
[TBL] [Abstract][Full Text] [Related]
10. Designer receptors enhance memory in a mouse model of Down syndrome.
Fortress AM; Hamlett ED; Vazey EM; Aston-Jones G; Cass WA; Boger HA; Granholm AC
J Neurosci; 2015 Jan; 35(4):1343-53. PubMed ID: 25632113
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
12. Forebrain Shh overexpression improves cognitive function and locomotor hyperactivity in an aneuploid mouse model of Down syndrome and its euploid littermates.
Gao FJ; Klinedinst D; Fernandez FX; Cheng B; Savonenko A; Devenney B; Li Y; Wu D; Pomper MG; Reeves RH
Acta Neuropathol Commun; 2021 Aug; 9(1):137. PubMed ID: 34399854
[TBL] [Abstract][Full Text] [Related]
13. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.
Ardestani PM; Evans AK; Yi B; Nguyen T; Coutellier L; Shamloo M
Neuropharmacology; 2017 Apr; 116():371-386. PubMed ID: 28089846
[TBL] [Abstract][Full Text] [Related]
14. An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.
Belichenko PV; Madani R; Rey-Bellet L; Pihlgren M; Becker A; Plassard A; Vuillermot S; Giriens V; Nosheny RL; Kleschevnikov AM; Valletta JS; Bengtsson SK; Linke GR; Maloney MT; Hickman DT; Reis P; Granet A; Mlaki D; Lopez-Deber MP; Do L; Singhal N; Masliah E; Pearn ML; Pfeifer A; Muhs A; Mobley WC
PLoS One; 2016; 11(3):e0152471. PubMed ID: 27023444
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome.
Hamlett ED; Ledreux A; Gilmore A; Vazey EM; Aston-Jones G; Boger HA; Paredes D; Granholm AE
Neurobiol Dis; 2020 Feb; 134():104616. PubMed ID: 31678403
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome.
Rueda N; Flórez J; Martínez-Cué C
Behav Brain Res; 2008 Apr; 188(2):355-67. PubMed ID: 18178265
[TBL] [Abstract][Full Text] [Related]
17. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
[TBL] [Abstract][Full Text] [Related]
18. Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome.
Smith GK; Kesner RP; Korenberg JR
Hippocampus; 2014 Mar; 24(3):354-62. PubMed ID: 24339224
[TBL] [Abstract][Full Text] [Related]
19. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.
Bianchi P; Ciani E; Guidi S; Trazzi S; Felice D; Grossi G; Fernandez M; Giuliani A; Calzà L; Bartesaghi R
J Neurosci; 2010 Jun; 30(26):8769-79. PubMed ID: 20592198
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABA
Duchon A; Gruart A; Albac C; Delatour B; Zorrilla de San Martin J; Delgado-García JM; Hérault Y; Potier MC
Br J Pharmacol; 2020 Mar; 177(5):1106-1118. PubMed ID: 31652355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
